Trial Profile
A Phase I Trial to Evaluate the Safety and Immunogenicity of an Influenza Vaccination Strategy Including a H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs H3N2 M2SR influenza vaccine-FluGen (Primary) ; Influenza virus vaccine
- Indications Influenza A virus infections
- Focus Adverse reactions
- 01 Oct 2020 Status changed from active, no longer recruiting to completed.
- 24 Oct 2019 Planned End Date changed from 31 Jul 2019 to 31 Oct 2020.
- 24 Oct 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Oct 2020.